UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.031

Sortiert nach

Lack of activity of recombinant HIF prolyl hydroxylases (PHDs) on reported non-HIF substrates

eLife, 2019-09, Vol.8

2019

Link zum Volltext

Verfügbarkeit prüfen

Lutetium-177-PSMA-617: A Vision of the Future

Cancer biology & therapy, 2022-12, Vol.23 (1), p.186-190

2022

Link zum Volltext

Verfügbarkeit prüfen

Drug interactions in cancer therapy

Nature reviews. Cancer, 2006-07, Vol.6 (7), p.546-558

2006

Link zum Volltext

Verfügbarkeit prüfen

Clinical protocol: Feasibility of evaluating abemaciclib neuropharmacokinetics of diffuse midline glioma using intratumoral microdialysis

PloS one, 2023-09, Vol.18 (9), p.e0291068-e0291068

2023

Link zum Volltext

Verfügbarkeit prüfen

Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment

Journal of clinical pharmacology, 2016-12, Vol.56 (12), p.1484-1499

2016

Link zum Volltext

Verfügbarkeit prüfen

Resistance to second-generation androgen receptor antagonists in prostate cancer

Nature reviews. Urology, 2021-04, Vol.18 (4), p.209-226

2021

Link zum Volltext

Verfügbarkeit prüfen

Single whole genome sequencing analysis blazes the trail for precision medicine

Cancer biology & therapy, 2022-12, Vol.23 (1), p.134-135

2022

Link zum Volltext

Verfügbarkeit prüfen

Validation of Analytic Methods for Biomarkers Used in Drug Development

Clinical cancer research, 2008-10, Vol.14 (19), p.5967-5976

2008

Link zum Volltext

Verfügbarkeit prüfen

Expression of OATP family members in hormone-related cancers: potential markers of progression

PloS one, 2011-05, Vol.6 (5), p.e20372-e20372

2011

Link zum Volltext

Verfügbarkeit prüfen

In memoriam Michelle A. Rudek (1972–2023)

Clinical and translational science, 2024-01, Vol.17 (1), p.e13705-n/a

2024

Link zum Volltext

Verfügbarkeit prüfen

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

Journal of clinical oncology, 2008-03, Vol.26 (7), p.1148-1159

2008

Link zum Volltext

Verfügbarkeit prüfen

Reactive astrocytic S1P3 signaling modulates the blood-tumor barrier in brain metastases

Nature communications, 2018-07, Vol.9 (1), p.2705-18, Article 2705

2018

Link zum Volltext

Verfügbarkeit prüfen

Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy

Clinical cancer research, 2011-02, Vol.17 (4), p.907-917

2011

Link zum Volltext

Verfügbarkeit prüfen

Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies

British journal of cancer, 2023-10, Vol.129 (9), p.1389-1396

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

Journal of clinical oncology, 2009-11, Vol.27 (32), p.5410-5417

2009

Link zum Volltext

Verfügbarkeit prüfen

Drugging the undruggable: activity-based protein profiling offers opportunities for targeting the KLK activome

Cancer biology & therapy, 2022-12, Vol.23 (1), p.136-138

2022

Link zum Volltext

Verfügbarkeit prüfen

Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation

Proceedings of the National Academy of Sciences - PNAS, 2009-05, Vol.106 (21), p.8573-8578

2009

Link zum Volltext

Verfügbarkeit prüfen

Antibody–drug conjugates for cancer

The Lancet (British edition), 2019-08, Vol.394 (10200), p.793-804

2019

Link zum Volltext

Verfügbarkeit prüfen

Pharmacogenomics Testing in Phase I Oncology Clinical Trials: Constructive Criticism Is Warranted

Cancers, 2022-02, Vol.14 (5), p.1131

2022

Link zum Volltext

Verfügbarkeit prüfen

Structural basis for binding of the renal carcinoma target hypoxia-inducible factor 2α to prolyl hydroxylase domain 2

Proteins, structure, function, and bioinformatics, 2023-11, Vol.91 (11), p.1510-1524

2023

Link zum Volltext

Verfügbarkeit prüfen

Safety and feasibility of long-term intravenous sodium nitrite infusion in healthy volunteers

PloS one, 2011-01, Vol.6 (1), p.e14504

2011

Link zum Volltext

Verfügbarkeit prüfen

Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol)

Clinical cancer research, 2005-06, Vol.11 (11), p.4136-4143

2005

Link zum Volltext

Verfügbarkeit prüfen

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses

Journal for immunotherapy of cancer, 2019-07, Vol.7 (1), p.197-8, Article 197

2019

Link zum Volltext

Verfügbarkeit prüfen

Important role of CYP2J2 in protein kinase inhibitor degradation: a possible role in intratumor drug disposition and resistance

PloS one, 2014-05, Vol.9 (5), p.e95532-e95532

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.031

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(899)
Mit Volltextzugriff
(833)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(1.028)
Japanisch
(78)
Deutsch
(2)
Chinesisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(704)
Life Sciences & Biomedicine
(682)
Humans
(595)
Oncology
(426)
Male
(380)
Biological And Medical Sciences
(245)
Medical Sciences
(241)
Middle Aged
(217)
Female
(194)
Aged
(193)
Pharmacology & Pharmacy
(193)
Pharmacology. Drug Treatments
(165)
Adult
(149)
Animals
(139)
Antineoplastic Agents
(131)
Cancer
(124)
Prostate Cancer
(119)
Chemotherapy
(108)
Prostatic Neoplasms - Drug Therapy
(108)
Tumors
(106)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Lack of activity of recombinant HIF prolyl hydroxylases (PHDs) on reported non-HIF substrates

Lutetium-177-PSMA-617: A Vision of the Future

Drug interactions in cancer therapy

Clinical protocol: Feasibility of evaluating abemaciclib neuropharmacokinetics of diffuse midline glioma using intratumoral microdialysis

Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment

Resistance to second-generation androgen receptor antagonists in prostate cancer

Single whole genome sequencing analysis blazes the trail for precision medicine

Validation of Analytic Methods for Biomarkers Used in Drug Development

Expression of OATP family members in hormone-related cancers: potential markers of progression

In memoriam Michelle A. Rudek (1972–2023)

Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

Reactive astrocytic S1P3 signaling modulates the blood-tumor barrier in brain metastases

Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy

Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

Drugging the undruggable: activity-based protein profiling offers opportunities for targeting the KLK activome

Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation

Antibody–drug conjugates for cancer

Pharmacogenomics Testing in Phase I Oncology Clinical Trials: Constructive Criticism Is Warranted

Structural basis for binding of the renal carcinoma target hypoxia-inducible factor 2α to prolyl hydroxylase domain 2

Safety and feasibility of long-term intravenous sodium nitrite infusion in healthy volunteers

Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol)

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses

Important role of CYP2J2 in protein kinase inhibitor degradation: a possible role in intratumor drug disposition and resistance

Suchergebnisse filtern